FDG PET/CT Demonstrates Malignant Fibrous Histiocytoma in a Patient with Nasopharyngeal Carcinoma after Radiation Therapy

A 25-year-old young male is a victim of undifferentiated nasopharyngeal carcinoma (NPC) s/p an 8,200 cGy external radiation therapy about 5 years ago, who was referred to our positron emission tomography (PET) center for evaluating a protruding mass in his nasal cavity. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging incidentally demonstrated a hypermetabolic lesion in the right nasal cavity and right maxillary sinus, which was suggestive of tumor recurrence. However, the surgical pathology report showed a picture of moderately differentiated sarcoma characterized by bizarre tumor giant cells, abnormal mitotic figure and intermixed with inflammatory cells. The immunohistochemical stains of the tumor cells showed positive for vimentin, which was compatible with malignant fibrous histiocytoma (MHF). Since radiation therapy is a well-known risk factor of MFH, which remind us that MFH should be ruled out in a NPC patient post radiotherapy and PET/CT scan is a valuable modality in detecting a second cancer, such as MFH. Furthermore, MFH usually happen to aged subgroup at limbs and retroperitoneum, our report presented rare case of a young male with MFH involving maxillary sinus and nasal cavity.

[1]  J. Eary,et al.  Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy , 2005, Cancer.

[2]  W. Vaalburg,et al.  Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.

[3]  Heiko Schöder,et al.  PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  W. Chapman,et al.  The Role of [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging in the Evaluation of Hepatocellular Carcinoma , 2003, The American surgeon.

[5]  G. Schulthess,et al.  Clinical molecular anatomic imaging : PET, PET/CT, and SPECT/CT , 2003 .

[6]  E. Patz,et al.  PET imaging in patients with bronchioloalveolar cell carcinoma. , 2002, Lung cancer.

[7]  J. Gibbs,et al.  Malignant Fibrous Histiocytoma: An Institutional Reviews , 2001, Cancer investigation.

[8]  A. Fischman,et al.  Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[9]  P. Marsden,et al.  Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography , 1999, The British journal of surgery.

[10]  J. Fraumeni,et al.  The epidemiology of soft tissue sarcoma. , 1997, Seminars in oncology.

[11]  M. Brennan,et al.  Radiation-associated sarcoma of bone and soft tissue. , 1992, Archives of surgery.

[12]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  S. Wallace,et al.  Magnetic resonance imaging of malignant fibrous histiocytoma. , 1989, Magnetic resonance imaging.

[14]  R. Beart,et al.  Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. , 1987 .

[15]  J. S. Laughlin,et al.  Imaging Studies of Patients with Malignant Fibrous Histiocytoma Using C-11-Alpha-Aminoisobutyric Acid (AIB) , 1987, Clinical nuclear medicine.

[16]  J. E. O'BRIEN,et al.  Malignant fibrous xanthomas , 1964, Cancer.